EADV Congress 2025 sessions spotlight
Updates
- Wed 17 Sep
- 14:15 - 15:45 CEST
- N01
Presentation details:
Towards a cure: Hit early, hit hard
Andrew Blauvelt, United States
Lecture description
Recent therapeutic developments for psoriasis have been incredible, with high numbers of patients safely achieving clear or almost clear skin. What’s next in the treatment of psoriasis? In this talk, Dr. Andy Blauvelt will highlight innovative therapeutic approaches that are aiming to achieve either long-term remissions or cure of psoriasis. “Hitting hard” means attacking the disease in more aggressive therapeutic ways than what is currently being utilized, whereas “hitting early” means treating patients within 1 year of onset of psoriasis, at a time when the disease is much more likely to respond to treatment and when there are higher chances of long-term remissions and cures. Combing the two strategies, hitting hard and hitting early, is a particularly interesting approach to treat psoriasis to optimize outcomes. Advances in these future approaches to treat psoriasis will be reviewed in this cutting edge talk by Dr. Blauvelt.
Updates
- Wed 17 Sep
- 16:00 - 17:30 CEST
- N01
Presentation details:
Treatment Resistance in Psoriasis
Lone Skov, Denmark
Lecture description
The treatment of moderate to severe psoriasis has significantly evolved in recent years, especially with the introduction of interleukin (IL)-17 and IL-23 inhibitors. Some patients exhibit a super response, maintaining cleared or nearly cleared skin for several years on the same treatment. However, some patients do not respond to the treatments, and others lose effectiveness after an initial positive response. In a subgroup of these patients, psoriasis is not controlled despite treatments with multiple treatments acting on multiple pathways. These patients are often referred to as treatment-resistant patients and remain a challenge in clinical practice. The reason for treatment-resistant psoriasis remains unknown. However, recent real-world studies have indicated that genetic markers such as HLA-C*06:02, the initial treatment response, and drug concentration post-initiation can predict treatment response. As we are improving our understanding of clinical, genetic, and immunological markers from blood and skin, we should be able to use these in helping guide treatment choices for the individual patients. This presentation will summarise the current understanding of treatment resistance, followed by an update on the latest advancements and their impact on clinical practice.
Presentation details:
Preventing and Management of Comorbidities in Psoriasis
Álvaro González-Cantero, Spain
Lecture description
Psoriasis is now well recognized as a systemic inflammatory disease, closely associated with a significantly increased risk of cardiometabolic comorbidities, including atherosclerosis, myocardial infarction, stroke, obesity, diabetes, and metabolic syndrome. Chronic systemic inflammation is a key driver of these associations, contributing to an accelerated cardiovascular risk that often goes underdiagnosed and undertreated in clinical practice.
This presentation will highlight the crucial importance of early identification and proactive management of cardiometabolic comorbidities in patients with psoriasis. We will review the most up-to-date evidence linking psoriasis and cardiovascular risk, discuss validated screening and prevention strategies, and outline integrated approaches for multidisciplinary management. Emphasis will be placed on the dermatologist’s pivotal role in recognizing early signs of systemic involvement and collaborating with primary care and cardiology to ensure comprehensive care that improves both dermatological and cardiovascular outcomes.
Learning Objectives:
- Understand the strong pathophysiological link between psoriasis and cardiometabolic comorbidities.
- Identify strategies for early cardiovascular risk assessment and prevention in patients with psoriasis.
- Learn practical approaches to multidisciplinary management of psoriasis with cardiometabolic involvement.
- Appreciate the impact of early intervention on patient survival, quality of life, and healthcare burden reduction.
Training and education
- Fri 19 Sep
- 08:30 - 10:00 CEST
- Paris Sud
Presentation details:
Treatment
Nina Magnolo, Germany
Lecture description
This lecture will cover standards and future directions in psoriasis treatment, highlighting the shift toward individualized care and early treatment start. Emphasis will be placed on biologic therapies, novel small molecules, and integrated management of comorbidities. The importance of early treatment initiation to improve short- and long-term outcomes will be pointed out.
Key Messages:
- Biologic therapies targeting IL-17 and IL-23 have revolutionized moderate-to-severe psoriasis treatment with high efficacy and favorable safety profiles.
- Oral options like Deucravacitinib, a TYK2 inhibitor, offer an alternative to injectables.
- Treatment selection should consider disease severity, comorbid conditions (e.g., psoriatic arthritis, metabolic syndrome) and patient preferences.
- Long-term management requires regular monitoring and evaluation of treatment sustainability.
- Holistic care—addressing lifestyle, mental health, and comorbidities—is crucial for optimal outcomes.
- Importance of early treatment to prevent disease chronification, impaired quality of life and the development of comorbidities.